Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Atorvastatin Calcium in Atherosclerosis: NCT06785974 Clinical Landscape Report 2026
15 October 2026
NCT06785974 clinical landscape for Atherosclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Albumin-Bound Paclitaxel in Triple Negative Breast Cancer: NCT06786026 Clinical Landscape Report 2026
15 October 2026
NCT06786026 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Blinatumomab in Systemic Lupus Erythematosus: NCT06789107 Clinical Landscape Report 2026
15 October 2026
NCT06789107 clinical landscape for Systemic Lupus Erythematosus: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
GPNMB-targeting Chimeric Antigen Receptor T-Cell Therapy(AHS Cancer Control Alberta) in Alveolar Soft Part Sarcoma: NCT06789081 Clinical Landscape Report 2026
15 October 2026
NCT06789081 clinical landscape for Alveolar Soft Part Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
OKN-4395 in Solitary Fibrous Tumors: NCT06789172 Clinical Landscape Report 2026
15 October 2026
NCT06789172 clinical landscape for Solitary Fibrous Tumors: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
VK-2019 in Diffuse large B-cell lymphoma refractory: NCT06789159 Clinical Landscape Report 2026
15 October 2026
NCT06789159 clinical landscape for Diffuse large B-cell lymphoma refractory: endpoints, sponsor, phase, geography, readouts, asset context and development wh…
9 min read
SIM-0505 in Locally Advanced Malignant Solid Neoplasm: NCT06792552 Clinical Landscape Report 2026
15 October 2026
NCT06792552 clinical landscape for Locally Advanced Malignant Solid Neoplasm: endpoints, sponsor, phase, geography, readouts, asset context and development w…
9 min read
Loncastuximab tesirine in Diffuse large B-cell lymphoma refractory: NCT06788964 Clinical Landscape Report 2026
15 October 2026
NCT06788964 clinical landscape for Diffuse large B-cell lymphoma refractory: endpoints, sponsor, phase, geography, readouts, asset context and development wh…
9 min read
Rituximab in Diffuse large B-cell lymphoma refractory: NCT06792253 Clinical Landscape Report 2026
15 October 2026
NCT06792253 clinical landscape for Diffuse large B-cell lymphoma refractory: endpoints, sponsor, phase, geography, readouts, asset context and development wh…
9 min read
Lumrotatug in Systemic Lupus Erythematosus: NCT06791772 Clinical Landscape Report 2026
15 October 2026
NCT06791772 clinical landscape for Systemic Lupus Erythematosus: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Paclitaxel in Endometrial Carcinoma: NCT06795009 Clinical Landscape Report 2026
15 October 2026
NCT06795009 clinical landscape for Endometrial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ipilimumab in Melanoma: NCT06794775 Clinical Landscape Report 2026
15 October 2026
NCT06794775 clinical landscape for Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.